Natural Product (NP) Details
| General Information of the NP (ID: NP4240) | |||||
|---|---|---|---|---|---|
| Name |
Esculetin
|
||||
| Synonyms |
aesculetin; 6,7-dihydroxycoumarin; cichorigenin
Click to Show/Hide
|
||||
| Species Origin | Fraxinus chinensis ... | Click to Show/Hide | |||
| Fraxinus chinensis | |||||
| Disease | Renal cell carcinoma [ICD-11: 2C90] | Investigative | [1] | ||
| Structure |
|
Click to Download Mol2D MOL |
|||
| ADMET Property |
Absporption
Caco-2 Permeability
-4.787
MDCK Permeability
-4.728
PAMPA
++
HIA
- - -
Distribution
VDss
-0.305
PPB
59.2%
BBB
- - -
Metabolism
CYP1A2 inhibitor
-
CYP1A2 substrate
- - -
CYP2C19 inhibitor
- - -
CYP2C19 substrate
-
CYP2C9 inhibitor
- - -
CYP2C9 substrate
++
CYP2D6 inhibitor
- - -
CYP2D6 substrate
- -
CYP3A4 inhibitor
- -
CYP3A4 substrate
- -
CYP2B6 inhibitor
- -
CYP2B6 substrate
- - -
CYP2C8 inhibitor
++
HLM Stability
+
Excretion
CLplasma
12.916
T1/2
1.457
Toxicity
DILI
++
Rat Oral Acute Toxicity
-
FDAMDD
+
Respiratory
+
Human Hepatotoxicity
-
Ototoxicity
- -
Drug-induced Nephrotoxicity
- - -
Drug-induced Neurotoxicity
- - -
Hematotoxicity
- -
Genotoxicity
+++
Tips: 1. For the classification endpoints, the prediction probability values are transformed into six symbols: 0-0.1 (- - -), 0.1-0.3 (- -), 0.3-0.5 (-), 0.5-0.7 (+), 0.7-0.9 (++), and 0.9-1.0 (+++).
2. Additionally, the corresponding relationships of the three labels are as follows: excellent; medium; poor.
Click to Show/Hide
|
||||
| Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product | |||||
| Formula |
C9H6O4
|
||||
| PubChem CID | |||||
| Canonical SMILES |
C1=CC(=O)OC2=CC(=C(C=C21)O)O
|
||||
| InChI |
1S/C9H6O4/c10-6-3-5-1-2-9(12)13-8(5)4-7(6)11/h1-4,10-11H
|
||||
| InChIKey |
ILEDWLMCKZNDJK-UHFFFAOYSA-N
|
||||
| CAS Number |
CAS 305-01-1
|
||||
| Herb ID | |||||
| ETMC ID | |||||
| SymMap ID | |||||
| TCMSP ID | |||||
| TTD Drug ID | |||||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. A List of Drug(s) Whose Efficacy can be Enhanced by This NP | ||||||
| TNF-related apoptosis inducing ligand | Lung cancer | Click to Show/Hide the Molecular Data of This Drug | ||||
| Augmenting Drug Sensitivity | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [2] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Up-regulation | Expression | TRAIL-R2 | Molecule Info |
Pathway MAP
|
|
| In-vitro Model | SAS | CVCL_1675 | Tongue squamous cell carcinoma | Homo sapiens | ||
| Experimental
Result(s) |
Esculetin enhances TRAIL-induced apoptosis primarily through upregulation of DR5. | |||||
| 5-fluorouracil | Solid tumour/cancer | Click to Show/Hide the Molecular Data of This Drug | ||||
| Augmenting Drug Sensitivity | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [3] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Down-regulation | Expression | CCND1 | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Expression | CDH2 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | CTNNB1 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | MYC | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | PCNA | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | WNT3A | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | Caco-2 | CVCL_0025 | Colon adenocarcinoma | Homo sapiens | ||
| HCT 116 | CVCL_0291 | Colon carcinoma | Homo sapiens | |||
| SW480 | CVCL_0546 | Colon adenocarcinoma | Homo sapiens | |||
| HT-29 | CVCL_0320 | Colon adenocarcinoma | Homo sapiens | |||
| In-vivo Model | Animal models were constructed by injecting HCT-116 cells in the right flank of nude mice. | |||||
| Experimental
Result(s) |
EST combined with 5-FU could increase the inhibitory effect of 5-FU on HCT-116 cells proliferation, migration and epithelial-mesenchymal transition. | |||||